We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,679

Third Circuit Clarifies Pleading Standard in Pay-For-Delay Suits
  • Stark & Stark
  • USA
  • September 12 2017

A Third Circuit opinion in the In re: Lipitor Antitrust Litigation reinstated the pay-for-delay lawsuit accusing pharmaceutical companies Pfizer Inc


Qualcomm and Apple Further Their Dispute About Whether Certain Patents Are, In Fact, Disputed
  • Vinson & Elkins LLP
  • USA
  • August 30 2017

A series of motions in the ongoing battle between tech blue chips Qualcomm and Apple about whether the Southern District of California (or any


Third Circuit Holds No Sham Litigation or Unlawful Reverse Payment in Wellbutrin XL Litigation
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • August 25 2017

The Third Circuit recently affirmed the grant of summary judgment to GlaxoSmithKline (“GSK”) in the nearly 10-year-old Wellbutrin XL Antitrust


The Supreme Court’s Decision in Amgen v. Sandoz: Clear Guidance and Open Questions for Biosimilars
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • July 21 2017

As we previously reported here, earlier this year the Supreme Court agreed to hear its first case arising under the Biosimilars Price Competition and


Major U.S. court decisions change patent landscape for Canadian companies
  • Osler Hoskin & Harcourt LLP
  • Canada, USA
  • July 6 2017

For many Canadian technology companies, the United States market is the most commercially important, yet it can be fraught with the risk of being sued


The Supreme Court Delivers a Win for Biosimilar Manufacturers in Sandoz v. Amgen
  • Baker & Hostetler LLP
  • USA
  • June 28 2017

On June 12, 2017, the Supreme Court issued a unanimous opinion in Sandoz v. Amgen, interpreting key provisions of the Biologics Price Competition and


Does Amgen Have Viable State Law Claims Against Sandoz Arising From The Zarxio Biosimilar Patent Dispute?
  • Foley & Lardner LLP
  • USA
  • June 27 2017

In Sandoz Inc. v. Amgen Inc. (which you can read more about here), the Supreme Court held that 42 USC 262(l)(9)(C) sets forth the exclusive federal


Supreme Court: Biosimilar Applicants May Provide Commercial Marketing Notice Before FDA Approval
  • Jones Day
  • USA
  • June 21 2017

Intended to provide a faster route to approval for generic biologics, the Biologics Price Competition and Innovation Act, was the basis for a


Third Circuit Declines to Send Pay-for-Delay Litigation to Federal Circuit
  • McDermott Will & Emery
  • USA
  • May 25 2017

Addressing questions of federal jurisdiction, the US Court of Appeals for the Third Circuit ruled that it, and not the US Court of Appeals for the


Commission Holds Oral Argument on Dismissal of Antitrust Claims in Section 337 Case
  • Hogan Lovells
  • USA
  • May 2 2017

On April 20, 2017, the Commission held an oral argument in connection with its review of an Administrative Law Judge’s decision to grant Chinese